IMS Health in the News
Pharma Voice, January 2013
Insights from Angeliki Cooney and Rob Hollis are included in this article on how the commercial pharma industry is actively engaged in how accountable care organizations (ACOs) deliver healthcare to Medicare patients. ACOs, which deliver integrated and coordinated care to Medicare patients, focus on evidence- and protocol-based models to drive improved treatment quality and cost savings.
Pharmaceutical Commerce, September/October 2012
Chris Leibfreid and Suzann Sullivan discuss how co-pay cards and other discounting programs can optimize an organization’s rebate spend and improve contract pull-through at the local level.
PM360, September 2012
Jody Fisher discusses how metrics from anonymous patient level data can be developed to provide a rapid assessment that examines regional areas where uptake of market share is not meeting expectations for the GERD market.
PharmaVOICE, September 2012
Big data, the avalanche of healthcare information on its way, represents a significant opportunity for pharmaceutical manufacturers. John Busalacchi and Eileen Moyer discuss how new sources of information, including electronic medical records, social media, real-world evidence, personalized medicine, and track-and trace systems, promise companies better clinical and commercial insights for competitive advantage.
pharmaphorum, September 2012
IMS believes that the threshold of $1bn for a blockbuster drug is completely outdated and a new, more realistic threshold would drastically cut the number of blockbuster products and change what it means to be successful in the future.
Medical Marketing & Media, August 2012
IMS’s Sarah Rickwood and Carolyn Gauntlett discuss the similarities in the competitive characteristics of SGLT-2 and DPP-IV diabetes medicines, honing in on the significant learning opportunities, and the successes and failures from recent launches, that companies can apply to gain an advantage in a highly competitive class of medicines.
Major media reports on the IMS Institute’s latest forecast for global spending on medicines through 2016. Michael Kleinrock discusses key aspects of the IMS Institute’s report.
PM360, June 2012
Aimee Ruscio and Catherine Balderston McGuiness discuss determining the market size of complex markets using anonymized, longitudinal, patient-level data.
American Medical News, June 26, 2012
An examination of health care spending habits conducted by the Kaiser Family Foundation found that health care costs worry even patients with insurance and relatively high incomes. The story cites data from the IMS Institute related to declining physician office visits between 2009 and 2011.
Report by the U.S. House of Representatives, June 15, 2012
The IMS Institute for Healthcare Informatics Report, Drug Shortages: A Closer Look at Products, Suppliers and Volume Volatility, is referenced in this U.S. House of Representatives report on the U.S. drug shortages crisis.
Bloomberg, June 12, 2102
The Japanese government and the pharmaceutical industry have worked to speed up drug approvals in Japan where a complex regulatory environment had delayed treatments for an aging population for years. IMS’s Alan Johnson discusses industry growth and the complexity of pricing drugs in Japan.
PM360, May 2012
Today, manufacturers can leverage anonymized, patient-level data (APLD) to further refine their prescriber evaluation methods rather than relying on looking at historical prescribing volumes. Alex Baranov and Heather von Allmen define methods for identifying physicians who fit a target profile or who treat the patients of most value to a brand team.
The Pink Sheet, May 21, 2012
Generic versions of Bristol-Myers Squibb/Sanofi’s blockbuster clot-buster clopidogrel launched in the U.S. May 17, but the companies are helping some patients continue on the brand by covering the high out-of-pocket costs. Following Pfizer’s success retaining share of Lipitor, industry is paying close attention to brand retention programs. IMS’s Suzanne Sullivan offers commentary about Lipitor and similar drugs that also faced loss of exclusivity in recent years.
Pharmaceutical Executive, May 2012
New sources of clinical and commercial information have proliferated the pharmaceutical industry, requiring companies to become technology agnostic. Don Ragas discusses the benefits and challenges of “big data” in this contributed article.
Pharmaceutical Commerce, May/June 2012
While cancer remains the second leading cause of death in the U.S., the survival rate has been rising. Jane Quigley offers insights into the complexities and dynamics of the oncology market.
PharmaVOICE, May 2012
Pharmaceutical marketers are continuing to look for ways to drive cost savings and return on investment for their marketing programs. In this PharmaVOICE roundtable discussion, Gregory Ford discusses regional marketing segmentation and strategies.
BeyeNETWORK, May 14, 2012
Pete Harbin discusses how pharmaceutical manufacturers can benefit from commercial analytics in this spotlight feature article.
Pharmaphorum, May 2012
The years immediately preceding a pharmaceutical product launch are arguably one of the riskiest periods in business and “getting it right” has never been more essential. IMS experts discuss the importance of the patient journey – a powerful framework for understanding the market and patient experience – in driving brand growth.
Pharmaphorum, May 2, 2012
The ability of mobile devices to connect the customer, field sales and central management will significantly shape the future of sales force effectiveness (SFE), in the pharmaceuticals market, in the coming years. This article and video uncovers the changing SFE landscape in pharma.
Eye on FDA, May 1, 2012
The issue of drug shortages surfaces periodically in the news and in policy circles, prompting both FDA and Administration officials to various actions. IMS Institute executive director Murray Aitken discusses the U.S. drug shortage issue with Eye on FDA’s Mark Senak.
PM360, April 2012
The overactive bladder (OAB) market is one familiar to most because of catchy jingles in direct-to-consumer advertising campaigns. Melissa Leonhauser analyzes the current leaders and Pfizer’s and AstraZeneca’s strategies to ensure successful futures in the market.
World Health Care Congress, April 16, 2102
This video features discussion by Murray Aitken about the importance of understanding the spending and utilization patterns for healthcare services among privately insured individuals under age 65 .
National Public Radio, SHOTS Blog, April 5, 2012
The IMS Institute report, The Use of Medicines in the United States: A Review of 2011, provides the context for the NPR SHOTS blog story about a slowdown in spending for prescription medications in the U.S.
Associated Press, April 4, 2012
Nine medical societies representing nearly 375,000 physicians are challenging the widely held perception that more healthcare is better, releasing lists of tests and treatments that their members should no longer automatically order. The IMS Institute’s report, Healthcare Spending Among Privately Insured Individuals Under Age 65 is sourced stating that 5 percent of patients accounted for half the total costs among privately insured people.
PharmExecBlog, April 4, 2012
Provisions of the Affordable Care Act drove out-of pocket costs down, while increasing drug spending among 19 to 25-year-olds in 2011. Michael Kleinrock is quoted and a chart that shows changes in prescriptions by patient age are cited throughout this article.
The New York Times, April 4, 2012
Patients cut back on prescription drugs and doctor visits last year, a sign that many Americans are still struggling to pay for healthcare despite economic recovery. Michael Kleinrock discusses the IMS Institute’s analysis of key spending and consumption trends for the U.S. healthcare system.
Bloomberg, April 4, 2012
U.S. senior citizens are filling fewer prescriptions for drugs as out-of-pocket costs rise in a weak economy, undercutting a record level of new product introductions by drug companies. The IMS Institute report, The Use of Medicines in the United States, and quotes by Michael Kleinrock inform reporting for this story.
PM360, March 2012
Prescriptions dispensed in hospitals can have an extended impact on a brand’s success as many patients receive prescriptions to fill afterwards at a retail pharmacy. Gregory Ford explains how the impact of hospital prescribing shouldn’t be underestimated and how using anonymous patient-level data allows brand teams to identify strategies to improves their success.
PM360, February 2012
In this installment of PM360’s MarketWatch series, Melissa Leonhauser evaluates the factors affecting success of brands in the hypertension market and demonstrates how excellent managed care coverage has boosted prescriptions for the leading angiotensin receptor blockers (ARBs).
CBS Evening News, February 14, 2012
Thousands of children count on methotrexate to fight the childhood cancer, acute lymphoblastic leukemia, but supplies are running dangerously low. Details from the IMS Institute’s drug shortages report is featured in this news story.
The Los Angeles Times, February 28, 2012
California and other states should consider the medical care used by the highest-cost patients who battle cancer and other chronic conditions when setting essential benefits under federal reform. Dan Malloy comments the impact of high-cost patients for this Los Angeles Times article.
The Huffington Post, February 28, 2012
Health insurance companies are testing ways to provide coverage to the people they can no longer avoid: working-age people with the biggest medical bills. The IMS Institute report helps inform reporting for this story.
Drug Store News, February 28, 2012
Lowering health costs will require a greater understanding of differences between two distinct groups of patients. IMS’s Murray Aitken is quote in this story and data from the report related to pharmacy services is cited.
The New York Times, February 28, 2012
One percent of patients account for more than 25 percent of healthcare spending among the privately insured, with medical bills nearing $100,000. The IMS Institute’s newest report, Spending Among Privately Insured Individuals Under Age 65, and commentary by Dan Malloy is featured.
Pharmaceutical Executive Europe, February 22, 2012
Major pharmaceutical companies are scrambling to meet the challenge of supplementing the clinical trial with “real world” evidence. IMS’s Jon Resnick discusses how to best advance the use of real-world evidence and IMS’s European collaboration with AstraZeneca.
PharmaFocus Reports, February 2012
South Africa offers distinct opportunities to launch new drugs and conduct clinical research related to pharmaceuticals. Omar Ehsan, Linda Reid and Symon Vokes discuss South Africa’s pharmaceutical market, offering perspective on key trends and dynamics.
PharmaVoice, February 2012
Generics continue to impact all areas of the pharmaceutical market. Alan Sheppard discusses the patent cliff and its impact on branded medicines.
PharmaVoice, February 2012
Biosimilars could amount to a multi-billion dollar market in the US, but uncertainty still exists as manufacturers wait for guidance from the FDA. Alan Sheppard comments about opportunities and challenges facing manufactures.
Modern Healthcare, January 23, 2012
IMS annual rankings for the top 100 Integrated Health Networks are published.
PM360, January 2012
In the latest installment of PM360’s MarketWatch series, Melissa Leonhauser analyzes the dynamics affecting the antipsychotic market and highlights how some of the top brands have been able to successfully compete against strong, lower-priced competition.
Pharmaceutical Commerce, January 2012
Demand for generic medicines is expected to reach $400 to $450 billion by 2015, with nearly 70 percent of this demand coming from the pharmerging economies. Alan Sheppard shares his insight on the major drivers of growth for the global generics market.
PM360, December 2011
To effectively reach and sell to physicians, facilities, and organizations, brand teams need an understanding of provider-provider relationships. Melissa Leonhauser explains how anonymous patient-level data provides previously unavailable insight into the informal links and relationships between providers.
USAToday, November 29, 2011
Pfizer has devised discounts and incentives for patients, insurers and companies that process Lipitor prescriptions that will, at least for the next six months, give patients access to the brand name drug for about the same cost as generics. Michael Kleinrock comments on Pfizer’s strategy and the benefits Lipitor brings to patients.
PM360, November 2011
Marketers who want their new brands to excel need to choose KPIs that go beyond the conventional metrics of sales, share, and growth. Build the right combination of leading and lagging indicators to define and track launch success, and show instantly where to make changes to correct the launch trajectory.
National Public Radio: The TakeAway, November 30, 2011
Millions of Americans taking Lipitor will be given a choice to stay on the medication or switch to the generic, as the 20 year patent for the blockbuster prescription drug expires. And Pfizer, the drug’s maker, is moving quickly to keep patients on the name brand. The IMS Institute’s Michael Kleinrock discusses Pfizer’s strategy and the benefits that Lipitor continues to deliver to patients.
Eye on FDA, November 15, 2011
A study released today on U.S. drug shortages sheds a more granular light on what has occurred. The study, conducted by the IMS Institute for Healthcare Informatics – Drug Shortages: A Closer Look at Products, Suppliers and Volume Volatility - examines data to assess some of the underpinning characteristics of the shortage and to make some recommendations.
SHOTS, NPR Health Blog, November 15, 2011
Persistent shortages of life-saving drugs led President Obama to issue an executive order last month to try and ease what one administration official called a "dire public health situation" that has created problems for patient care.
A new analysis from the IMS Institute about drug shortages shows that 550,000 U.S. cancer patients alone are impacted by the shortage, and joins the discussion to recommend a better system to warn hospitals, doctors and pharmacists about medicines that may become in short supply.
The IMS Institute looks at the current drug shortages problem in the United States and examines the magnitude of the problem, its causes and ways to prevent or resolve shortages in the future.
Medscape Today News, November 14, 2011
A new report issued by the IMS Institute for Healthcare Informatics shows that 168 drugs are currently in short supply, and most of the shortage clusters around 4 key areas. The report coincided with a presentation here at the American Medical Association (AMA) 2011 Interim Meeting by Bona Benjamin, BS Pharm, director of medication use quality improvement for the American Society of Health-System Pharmacists (ASHP).
Reuters, November 14, 2011
The shortage of medicines in the United States that has recently gained the attention of President Obama is worst among about 75 products, while supplies of other scare drugs remains stable or growing, according to a new report from the IMS Institute.
Pharmaceutical Commerce, October 2011
The number of patients suffering from diabetes continues to rise and at an alarming rate. Driven by the urgency and need to innovate, new therapies, including the introduction of non-insulin anti-diabetic medications, are delivering breakthrough treatment options to patients, providers, and payers.
Emerging Strategies: Faced with Change, Pharmaceutical Firms Shift Business Mix to Generics and Emerging Markets
Chemical & Engineering News, October 2011
Between now and 2015, about $138 billion in drug sales across eight major developed markets will be at risk to generic competition. Multinational pharmaceutical companies are looking to generic products and emerging markets, and much is riding on how well they balance their new and old businesses.
PharmaVoice, October 2011
With a diverse population, thriving research environment, strong infrastructure, and access into the rest of Africa, South Africa offers significant advantages for global pharmaceutical manufacturers.
Medical Marketing & Media, October 2011
Market trends and challenges for new and existing medicines in treating cancer are discussed in this MM&M feature. We highlight four key drivers for achieving commercial success when launching oncology therapies.
OTC Bulletin, September 2011
IMS research shows a pattern of rising prescription-generated sales and falling self-medication sales is now a well established trend in the UK, providing pharmaceutical manufacturers with an opportunity to develop and grow brands in the prescribed OTC channel.
GPhA Report, Sep 26, 2011
A study conducted by the IMS Institute for Healthcare Informatics for the Generics Pharmaceutical Association (GPhA) finds that generic versions of brand name drugs helped save the American healthcare system more than $931 Bn over the past decade.
PharmaVOICE, September 2011
For the “Letter From The Editor,” we share four innovative approaches pharma leaders can use to drive brand growth.
Pharmaceutical Commerce, August 2011
IMS research shows that the window of opportunity to set your launch trajectory remains incredibly short, with years of preparation judged in months. This article discusses the dynamic market, the foundation on which all new products build their trajectories. Penetrate it well and gain rapid uptake; fail and the trajectory will be flat.
Pharmaceutical Executive, August 2011
Our experts share their insights about anticipating risk, staying agile, understanding culture, and dropping the HQ comfort-zone mentality to achieve commercial excellence in the pharmerging markets.
PharmaPhorum, August 2011
Launch success for new oncology therapies has become more challenging, complicated by a maturing market and higher costs of access. Understanding the new “rules of the game” can help pharmaceutical companies achieve commercial success.
PM360, July 2011
New public-payer schemes are driving providers away from fee-for-service and toward outcome-based payments. With the rules of the road changing, companies must refine their commercial strategies by using real-world evidence that demonstrates product value and improves quality and patient outcomes.
The Hill, July 15, 2011
The Hill reports on the IMS Institute report, Medicare Part D at Age Five: What Has Happened to Seniors’ Prescription Drug Prices?
Reuters, July 15, 2011
The trend toward less costly generic drugs are identified as a key factor that could temper growing costs of the Medicare Part prescription program for seniors and disabled patients.
The Pink Sheet, July 11, 2011
The economic downturn continues to impact new drug launches. Increased pressure by payers and regulators, and greater availability of lower cost generics, are changing the game for how companies and analysts measure launch success.
Pharmaceutical Market Europe, May 2011
Turkey has always been a bridge between Europe and Asia with untapped promise in a variety of industries. We explore the unique opportunities this market offers and how pharmaceutical manufacturers can tap into its potential.
Life Science Leader, May 2011
Michel Denarie provides insights into using anonymized patient-level secondary data to more cost-effectively identify and recruit the right patient pools and physician investigators for clinical trials.
Managed Care, May 2011
Health plans have many options to improve how they handle these costly therapies. There have been improvements in the underlying medical claims data driving patient adherence research.
Reuters, May 18, 2011
Generics are identified as among the key market dynamics expected to drive healthcare spending through 2015.
PharmExecBlog, May 18, 2011
Estimated growth and the regulatory pathway for biosimilars in the U.S. are outlined.
Bloomberg, May 18, 2011
Bloomberg reports on the IMS Institute for Healthcare Informatics study, The Global Use of Medicines: Outlook through 2015, including extensive commentary on key drivers of future healthcare spending.
The Chicago Tribune, May 4, 2011
More than $100 billion in annual brand-name drug sales will be at risk for generic competition from 2011 to 2015. That's about one-third of the annual spending on all prescription drugs in the U.S., according to IMS data.
The TB Alliance and the Bill and Melinda Gates Foundation partnered with IMS on this published study, which concludes that the expansion of diagnosis and treatment in the public sector could have a greater impact in strengthening TB treatment outcomes.
Next Generation Pharma, April 2011
IMS Consulting Group's Chris Nickum details the path to more effective pharma commercial models and greater efficiency in promotional spend strategies.
Associated Press, April 19, 2011
The article features insights from the IMS Institute for Healthcare Informatics report, Use of Medicines in the United States: Review of 2010.
The Wall Street Journal Health Blog, April 19, 2011
Key market drivers in 2010, including generic growth and the dynamics around spending and the most widely prescribed products, are outlined, based on the IMS Institute for Healthcare Informatics study, The Use of Medicines in the United States: Review of 2010.
Reuters, April 19, 2011
The IMS Institute for Healthcare Informatics study, Use of Medicines in the United States: Review of 2010, is featured. In the story, Reuters cites the greater use of cheaper generic medicines, less spending on new therapies and fewer patients visiting doctors to begin treatments for chronic illnesses as key factors that contributed to the market's slowing growth.
Washington Business Journal, February 25, 2011
This article reports on the coming “patent cliff” and pharma’s preparedness strategies.
Biotechnology Healthcare, Winter 2010/2011
The use of evidence-based medical research to support greater healthcare transparency.
Managed Healthcare Executive, October 2010
Terri Bernacchi asserts that greater collaboration between pharma and payers is a “win-win” for both sets of stakeholders.
Pharmaceutical Commerce, October 2010
IMS’s Terri Bernacchi and Mark Wiseman on ways the pharmaceutical industry and payers can work together to achieve cost savings and better health outcomes for patients.
Pharmaceutical Executive, October 2010
How outsourcing analytic functions can drive commercial excellence and cost efficiencies.
Medical Marketing & Media, October 2010
Alan Hirshman describes the potential benefits of utilizing the specialty pharmacy channel in building patient relationships for specialty drugs, and offers guidance on where marketers can achieve the best ROI on their spend to this patient category.
Pharmaceutical Commerce, September/October 2010
How the pharmaceutical industry and payers can work together to achieve cost savings and better health outcomes for patients.
Pharmaceutical Executive, August 2010
IMS, Pfizer and Merck share their perspectives on the industry's expanding vision for emerging markets. Our consultants outline seven principles that will help drive success in both first- and second-tier emerging markets.
Pharmaceutical Commerce, May/June 2010
Creating commercial efficiencies is no longer about simply managing costs; it's about developing and implementing new commercial models that suit the new environment. IMS reviews a framework to guide new model development and shares examples of best practices and pitfalls.
Corporate Compliance Insights, May 10, 2010
Mark Linver on the areas biopharma and medical device companies must get right to meet state and federal aggregate spend reporting mandates: regulatory, process/policy/technology preparedness, data integration, operational change and information governance.
PM360, March 2010
A new tool to maximize ROI in consumer promotion, helping to make patient outreach more selective while supporting the most relevant physicians in their treatment decisions.
New York Times, March 17, 2010
Citing IMS’s report on 17 newly-identified pharmerging markets for pharmaceutical industry growth, this article reviews the factors impacting the growth challenges that pharma has faced and steps some companies are taking to capitalize on these markets.
Next Generation Pharma, March 2010
A review of the impact of managed care, patient and technology influences on healthcare practitioner decision-making.
Valor Economico, February 17, 2010
Perspectives on pharmaceutical market growth in Brazil.
(Click here for the English version).
The New York Times, February 15, 2010
The financial impact of patent expiries on branded drugs, and the growth opportunities in emerging markets.
Medical Marketing & Media, February 2010
How to achieve the right balance between access for patients and control over distribution.
Canadian Pharmaceutical Marketing, February 2010
Therapeutic insights and key trends by IMS on gastric-related diseases are highlighted in this article on the evolution of the Canadian PPI market.
Pharmaceutical Executive, January 2010
Current trends and challenges for the global pharmaceutical market in 2010.
MedAdNews ebulletin, February 2010
IMS’s Sydney Clark and Patrick Retif discuss the current challenges of today’s sales models and changes manufacturers will need to make to drive greater efficiencies in their businesses.